The tetrahydroxanthone-dimer phomoxanthone A is a strong inducer of apoptosis in cisplatin-resistant solid cancer cells.


Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
01 10 2019
Historique:
received: 09 05 2019
revised: 18 07 2019
accepted: 06 08 2019
pubmed: 25 8 2019
medline: 21 10 2020
entrez: 25 8 2019
Statut: ppublish

Résumé

Platinum compounds are the first-line therapy for many types of cancer. However, drug resistance has frequently been reported for and is a major limitation of platinum-based chemotherapy in the clinic. In the current study, we examined the anti-tumor activity of phomoxanthone A (PXA), a tetrahydroxanthone dimer isolated from the endophytic fungus Phomopsis longicolla, in several solid cancer cell lines and their cisplatin-resistant sub-cell lines. PXA showed strong cytotoxic effects with IC

Identifiants

pubmed: 31443950
pii: S0968-0896(19)30785-0
doi: 10.1016/j.bmc.2019.115044
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Xanthones 0
phomoxanthone A 0
CASP3 protein, human EC 3.4.22.-
CASP7 protein, human EC 3.4.22.-
Caspase 3 EC 3.4.22.-
Caspase 7 EC 3.4.22.-
Cisplatin Q20Q21Q62J
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115044

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Chenyin Wang (C)

Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.

Laura Engelke (L)

Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.

David Bickel (D)

Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.

Alexandra Hamacher (A)

Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.

Marian Frank (M)

Institute of Pharmaceutical Biology and Biotechnology, Heinrich Heine Universität Düsseldorf, 40225 Düsseldorf, Germany.

Peter Proksch (P)

Institute of Pharmaceutical Biology and Biotechnology, Heinrich Heine Universität Düsseldorf, 40225 Düsseldorf, Germany.

Holger Gohlke (H)

Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; John von Neumann Institute for Computing (NIC), Jülich Supercomputing Centre (JSC) & Institute for Complex Systems - Structural Biochemistry (ICS 6), Forschungszentrum Jülich GmbH, 52425 Jülich, Germany.

Matthias U Kassack (MU)

Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany. Electronic address: matthias.kassack@uni-duesseldorf.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH